Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physicians choice chemotherapy compared to trastuzumab in combination with physicians choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment

15680JZP598-303-MWHC-NCT06435429OpenPhase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physicians choice chemotherapy compared to trastuzumab in combination with physicians choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatmentJPZ598-303NCT06435429IndustrialAdultTreatmentIIIOtherWhitaker, KristenMedStar Health and GUMC; Medstar Washington Hospital Center : Stacy MalloyBreastOncology GroupMHRI Washington Cancer Institute10787Stacy MalloyStacy MalloyStacy.K.Malloy@medstar.net2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>